Repare Therapeutics Inc. (RPTX) Stock Price, Quote & News - Stock Analysis (2024)

Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024 Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition Repare Therapeutics Appoints Steven H. Stein, M.D. Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX Repare Therapeutics Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - RPTX Repare Therapeutics to Participate in Two Upcoming Investor Conferences ATTENTION Repare Therapeutics Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results Repare Therapeutics Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - RPTX Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX) Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664 Repare Therapeutics to Regain Global Rights to Camonsertib Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast